MedTrace Logo

Study to Prevent Postoperative Urinary Retention

NCT04491526 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2026-02-17

No results posted yet for this study

Summary

Post-operative urinary retention (POUR) is a common complication after inguinal hernia repair with a reported incidence up 34%. It can be described as the inability to initiate urination or properly empty one's bladder following surgery. It is usually self-limited, but it requires the use of catheterization to empty the bladder in order to prevent further injury to the bladder or kidneys and to relief the discomfort of a full bladder. Tamsulosin is a medication that is commonly used in men with urinary symptoms related to an enlarged prostate. There is some evidence to suggest that it may also potentially be beneficial for preventing post-operative urinary retention.

The purpose of this study is to determine if tamsulosin ("TAMSULOSIN Mepha Ret Depocaps 0.4 mg") is effective in preventing post-operative urinary retention following endoscopic total extraperitoneal inguinal hernia repair and its impact on hospital length of stay.

Conditions

  • Urinary Retention
  • Inguinal Hernia

Interventions

DRUG

TAMSULOSIN Mepha Ret Depocaps 0.4 mg

0.4mg/day Tamsulosin hydrochloride ("TAMSULOSIN Mepha Ret Depocaps 0.4 mg") from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)

DRUG

Control Intervention

One placebo capsule matching the active study drug per day from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery. (5+1+1)

Sponsors & Collaborators

  • Antonio Nocito, MD

    lead OTHER

Principal Investigators

  • Antonio Nocito, Prof · Kantonsspital Baden AG, Im Ergel 1, 5404 Baden, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2026-02-09
Completion
2026-02-09

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04491526 on ClinicalTrials.gov